GuidelineJAMA2020
Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement.
Guideline in JAMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
156 citing papers in PubMed, 2 syntheses or guidelines pooled it, 288 citations in OpenAlex.
- The prevalence of hepatitis C and hepatitis B in lesbian, gay, bisexual and transgender populations: a systematic review and meta-analysis.European journal of medical research · 2022Pooled it
- Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Guideline
- Expanding hepatitis C virus test uptake using self-testing among men who have sex with men in China: two parallel randomized controlled trials.BMC medicine · 2023Trial
- Effect of a Default Order vs an Alert in the Electronic Health Record on Hepatitis C Virus Screening Among Hospitalized Patients: A Stepped-Wedge Randomized Clinical Trial.JAMA network open · 2022Trial
- Behavioral interventions to improve population health outreach for hepatitis C screening: randomized clinical trial.BMJ (Clinical research ed.) · 2021Trial
- Using Lean-Facilitation to Improve Quality of Hepatitis C Testing in Primary Care.Journal of general internal medicine · 2021Trial
- Seroepidemiological Prevalence of Hepatitis B and C Virus Coinfection: A Large-Scale Retrospective Cohort Study in Istanbul.Diagnostics (Basel, Switzerland) · 2026Article
- IMPAACT 2041: Designing the Study of Glecaprevir/Pibrentasvir Treatment During Pregnancy.Open forum infectious diseases · 2026Article
- Trends in HCV Prevalence and Risk Factors Among People who Inject Drugs in Los Angeles County, 2012-2024.AIDS and behavior · 2026Article
- Article
- Development and validation of a machine learning model for evidence of prior or current HCV infection: a demographic screening approach for the US population.BMC public health · 2026Article
- Hepatitis C care cascade using direct-acting antivirals in rural new York State from 2013 to 2023: a retrospective observational study.BMC infectious diseases · 2026Observational
- Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES): Study protocol for a hybrid 1 stepped-wedge multibehavioral randomized trial.Contemporary clinical trials · 2026Article
- Hepatitis C Treatment by Early-Career US Family Physicians.Family medicine · 2026Article
- Recent Advances in the Epidemiology, Screening, and Management of Hepatitis C Virus Infection in Pregnancy.Gastroenterology & hepatology · 2026Article
- A Systematic Review and Narrative Synthesis of Factors Impacting Late Diagnosis of Chronic Hepatitis B and C.Health science reports · 2026Review
- Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US.Viruses · 2026Article
- Cost-Effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United States.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Trends in Utilization and Costs Following a Hepatitis C Elimination Initiative.JAMA network open · 2026Observational
- Hepatitis C Screening: A Health Technology Assessment.Ontario health technology assessment series · 2026Article
96 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- SummaryForPatientsIn
Authors and funding
17 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. HCV is associated with more deaths than the top 60 other reportable infectious diseases combined, including HIV. Cases of acute HCV infection have increased approximately 3.8-fold over the last decade because of increasing injection drug use and improved surveillance. Objective: To update its 2013 recommendation, the USPSTF commissioned a review of the evidence on screening for HCV infection in adolescents and adults. Population: This recommendation applies to all asymptomatic adults aged 18 to 79 years without known liver disease. Evidence Assessment: The USPSTF concludes with moderate certainty that screening for HCV infection in adults aged 18 to 79 years has substantial net benefit. Recommendation: The USPSTF recommends screening for HCV infection in adults aged 18 to 79 years. (B recommendation).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.